| Literature DB >> 33172446 |
Kidane Siele Embaye1, Saud Mohammed Raja2, Medhanie Haile Gebreyesus3, Matiwos Araya Ghebrehiwet4.
Abstract
BACKGROUND: Fine needle aspiration cytology is a simple, relatively accurate, non-invasive, and cost-effective method of diagnosing most breast pathologies. To date, there is no sufficient data depicting the distribution of breast lesions detected by fine needle aspiration cytology in our healthcare setting. The aim of this study was to elucidate the general distribution of breast lesions diagnosed by cytology test at Eritrean National Health Laboratory.Entities:
Keywords: Breast cancer; Breast lesions; Distribution; Eritrea; FNAC
Year: 2020 PMID: 33172446 PMCID: PMC7654611 DOI: 10.1186/s12905-020-01116-0
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.809
Sex and age distribution of study population who attended FNAC at ENHL
| Variable | Frequency | Percentage (%) |
|---|---|---|
| Gender | ||
| Female | 871 | 96.24 |
| Male | 34 | 3.76 |
| Total | 905 | 100 |
| Age group (in years) | ||
| ≤ 20 | 162 | 17.90 |
| 21–30 | 373 | 41.22 |
| 31–40 | 134 | 14.80 |
| 41–50 | 100 | 11.05 |
| 51–60 | 75 | 8.29 |
| > 60 | 61 | 6.74 |
| Total | 905 | 100 |
Clinical presentations of study participants
| Clinical symptom | Total ( | Percent | Female | Percent | Male | Percent |
|---|---|---|---|---|---|---|
| Lump | 892 | 98.56 | 859 | 98.62 | 34 | 100 |
| Pain | 107 | 11.82 | 99 | 11.37 | 8 | 23.53 |
| Lymph node enlargement | 33 | 3.65 | 32 | 3.67 | 1 | 2.94 |
| Nipple discharge | 29 | 3.20 | 27 | 3.09 | 2 | 5.88 |
| Skin changes | 17 | 1.88 | 16 | 1.83 | 1 | 2.94 |
| Retraction | 15 | 1.66 | 15 | 1.72 | 0 | 0 |
Overall and sex-specific frequency distribution of breast lesions diagnosed by FNAC
| DIAGNOSIS | Frequency | Percent | Female | Percent | Male | Percent |
|---|---|---|---|---|---|---|
| Fibroadenoma | 353 | 39.01 | 353 | 40.54 | 0 | 0 |
| Fibrocystic disease | 133 | 14.70 | 133 | 15.28 | 0 | 0 |
| Ductal carcinoma of the breast | 79 | 8.73 | 78 | 8.97 | 1 | 2.94 |
| Benign breast lesion, NOS | 56 | 6.19 | 52 | 5.97 | 4 | 11.78 |
| Suspicious for malignancy | 51 | 5.64 | 49 | 5.63 | 2 | 5.88 |
| Lipoma | 42 | 4.64 | 42 | 4.82 | 0 | 0 |
| Benign proliferative breast disease | 37 | 4.09 | 35 | 4.03 | 2 | 5.88 |
| Gynecomastia | 19 | 2.11 | 0 | 0 | 19 | 55.88 |
| Malignant breast lesion | 18 | 1.99 | 18 | 2.07 | 0 | 0 |
| Fat tissue | 17 | 1.88 | 15 | 1.72 | 2 | 5.88 |
| Galactocele | 16 | 1.77 | 16 | 1.84 | 0 | 0 |
| Unsatisfactory sample | 11 | 1.22 | 10 | 1.15 | 1 | 2.94 |
| Benign breast lesion with atypia | 10 | 1.10 | 9 | 1.03 | 1 | 2.94 |
| Breast abscess | 10 | 1.10 | 10 | 1.15 | 0 | 0 |
| Inflammatory breast disease | 9 | 0.99 | 9 | 1.03 | 0 | 0 |
| Phyllodes tumor | 6 | 0.66 | 6 | 0.69 | 0 | 0 |
| Atypical ductal hyperplasia | 5 | 0.55 | 5 | 0.57 | 0 | 0 |
| Mammary duct ectasia | 4 | 0.44 | 4 | 0.46 | 0 | 0 |
| Non-specific finding | 4 | 0.44 | 3 | 0.34 | 1 | 2.94 |
| Ductal hyperplasia | 3 | 0.33 | 3 | 0.34 | 0 | 0 |
| Intraductal papilloma | 3 | 0.33 | 3 | 0.34 | 0 | 0 |
| Lobular carcinoma | 3 | 0.33 | 3 | 0.34 | 0 | 0 |
| Cystic breast lesion | 2 | 0.22 | 2 | 0.23 | 0 | 0 |
| Fat necrosis | 2 | 0.22 | 2 | 0.23 | 0 | 0 |
| Granulomatous mastitis | 2 | 0.22 | 1 | 0.11 | 1 | 2.94 |
| Inflammatory carcinoma of the breast | 2 | 0.22 | 2 | 0.23 | 0 | 0 |
| Acute mastitis | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Colloid carcinoma of the breast | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Ectopic disease of the breast | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Fibroadenomatosis | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Fibrolipoma | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Fibroma | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Normal condition | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Scar tissue | 1 | 0.11 | 1 | 0.11 | 0 | 0 |
| Total | 905 | 100% | 871 | 100% | 34 | 100% |
NOS not otherwise specified
Distribution pattern of breast lesions in symptomatic patients at ENHL by age group (n = 905)
| Age group | Malignant | Suspicious | Atypical | Benign | Inadequate material | Total |
|---|---|---|---|---|---|---|
| ≤ 20 | 0 (0.0%) | 2 (1.2%) | 1 (0.6%) | 158 (97.6%) | 1 (0.6%) | 162 (100%) |
| 21–30 | 8 (2.1%) | 8 (2.1%) | 12 (3.2%) | 340 (91.3%) | 5 (1.3%) | 373 (100%) |
| 31–40 | 15 (11.2%) | 6 (4.5%) | 6 (4.5%) | 106 (79.1%) | 1 (0.7%) | 134 (100%) |
| 41–50 | 26 (26.0%) | 17 (17.0%) | 10 (10.0%) | 45 (45.0%) | 2 (2.0%) | 100 (100%) |
| 51–60 | 26 (34.7%) | 16 (21.3%) | 7 (9.3%) | 26 (34.7%) | 0 (0.0%) | 75 (100%) |
| > 60 | 26 (42.6%) | 9 (14.8%) | 3 (4.9%) | 19 (31.1%) | 4 (6.6%) | 61 (100%) |
| Total | 101 (11.2%) | 58 (6.4%) | 39 (4.3%) | 694 (76.7%) | 13 (1.4%) | 905 (100) |
ENHL Eritrean National Health Laboratory
Fig. 1Distribution of breast lesions according to their risk for malignancy and age category
Association between two-tier age category and risk of malignancy among study patients at ENHL
| Age category | N | High risk for malignancy | Low risk for malignancy | Chi-square value | |
|---|---|---|---|---|---|
| ≤ 40 years | 669 (73.9%) | 39 (24.5%) | 630 (84.5%) | 244.13 | < 0.001 |
| > 40 years | 236 (26.1%) | 120 (75.5%) | 116 (15.5%) | ||
| Total | 905 (100%) | 159 (100%) | 746 (100%) |
*Difference is significant at p < 0.001
Fig. 2Five-year trend of breast lesions in symptomatic patients at ENHL